- Home
- AIRT vs ASRT Comparison
AIRT vs ASRT Comparison
Compare AIRT & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ASRT
- Stock Information
- Founded
- AIRT 1980
- ASRT 1995
- Country
- AIRT United States
- ASRT United States
- Employees
- AIRT N/A
- ASRT N/A
- Industry
- AIRT Air Freight/Delivery Services
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- ASRT Health Care
- Exchange
- AIRT Nasdaq
- ASRT Nasdaq
- Market Cap
- AIRT 59.0M
- ASRT 57.9M
- IPO Year
- AIRT N/A
- ASRT 1997
- Fundamental
- Price
- AIRT $23.51
- ASRT $0.71
- Analyst Decision
- AIRT
- ASRT Strong Buy
- Analyst Count
- AIRT 0
- ASRT 2
- Target Price
- AIRT N/A
- ASRT $3.25
- AVG Volume (30 Days)
- AIRT 4.4K
- ASRT 232.8K
- Earning Date
- AIRT 08-13-2025
- ASRT 08-06-2025
- Dividend Yield
- AIRT N/A
- ASRT N/A
- EPS Growth
- AIRT N/A
- ASRT N/A
- EPS
- AIRT N/A
- ASRT N/A
- Revenue
- AIRT $291,850,000.00
- ASRT $119,001,000.00
- Revenue This Year
- AIRT N/A
- ASRT N/A
- Revenue Next Year
- AIRT N/A
- ASRT $11.91
- P/E Ratio
- AIRT N/A
- ASRT N/A
- Revenue Growth
- AIRT 1.75
- ASRT N/A
- 52 Week Low
- AIRT $14.56
- ASRT $0.51
- 52 Week High
- AIRT $26.70
- ASRT $1.54
- Technical
- Relative Strength Index (RSI)
- AIRT 52.88
- ASRT 54.09
- Support Level
- AIRT $22.06
- ASRT $0.66
- Resistance Level
- AIRT $24.50
- ASRT $0.79
- Average True Range (ATR)
- AIRT 1.01
- ASRT 0.03
- MACD
- AIRT 0.01
- ASRT 0.00
- Stochastic Oscillator
- AIRT 27.26
- ASRT 38.54
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.